Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
EAST RUTHERFORD, N.J., Sept. 06, 2016 -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a SEK 72 million ($9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in Sweden.
The investment includes the installation of new multi-purpose reactors ranging from 4m3 to 12m3 and upgrading of the control room within an existing plant on site. The new facilities will undergo validation and cGMP qualification ahead of the operational startup in Q4 2016. This extra capacity increases the large scale manufacturing capabilities of the Karlskoga facility, which supports clients’ development projects from R&D through to large scale commercial manufacturing.
“Our facility at Karlskoga is strategically important, both in Scandinavia and the wider European markets, and this investment is in response to an increase in demand for larger scale, multi-purpose manufacturing capabilities,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga. “By creating greater capacity within the current infrastructure, we have combined expansion and efficiency at the site, both of which will benefit our customers.”
The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to invest in small molecule API manufacturing across its global network of facilities.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Alex Maw Director, Marketing and Communications Phone: +44 7803 443 155 Email: [email protected]
